432 related articles for article (PubMed ID: 19284480)
21. Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene.
Sondhi D; Scott EC; Chen A; Hackett NR; Wong AM; Kubiak A; Nelvagal HR; Pearse Y; Cotman SL; Cooper JD; Crystal RG
Hum Gene Ther; 2014 Mar; 25(3):223-39. PubMed ID: 24372003
[TBL] [Abstract][Full Text] [Related]
22. Altered sensitivity of cerebellar granule cells to glutamate receptor overactivation in the Cln3(Δex7/8)-knock-in mouse model of juvenile neuronal ceroid lipofuscinosis.
Finn R; Kovács AD; Pearce DA
Neurochem Int; 2011 May; 58(6):648-55. PubMed ID: 21315126
[TBL] [Abstract][Full Text] [Related]
23. Evidence for phosphorylation of CLN3 protein associated with Batten disease.
Michalewski MP; Kaczmarski W; Golabek AA; Kida E; Kaczmarski A; Wisniewski KE
Biochem Biophys Res Commun; 1998 Dec; 253(2):458-62. PubMed ID: 9878558
[TBL] [Abstract][Full Text] [Related]
24. A novel c.1135_1138delCTGT mutation in CLN3 leads to juvenile neuronal ceroid lipofuscinosis.
Drack AV; Miller JN; Pearce DA
J Child Neurol; 2013 Sep; 28(9):1112-6. PubMed ID: 23877479
[TBL] [Abstract][Full Text] [Related]
25. The CLN3 gene is a novel molecular target for cancer drug discovery.
Rylova SN; Amalfitano A; Persaud-Sawin DA; Guo WX; Chang J; Jansen PJ; Proia AD; Boustany RM
Cancer Res; 2002 Feb; 62(3):801-8. PubMed ID: 11830536
[TBL] [Abstract][Full Text] [Related]
26. Localization and processing of CLN3, the protein associated to Batten disease: where is it and what does it do?
Pearce DA
J Neurosci Res; 2000 Jan; 59(1):19-23. PubMed ID: 10658181
[TBL] [Abstract][Full Text] [Related]
27. Tissue expression and subcellular localization of CLN3, the Batten disease protein.
Margraf LR; Boriack RL; Routheut AA; Cuppen I; Alhilali L; Bennett CJ; Bennett MJ
Mol Genet Metab; 1999 Apr; 66(4):283-9. PubMed ID: 10191116
[TBL] [Abstract][Full Text] [Related]
28. CLN3p impacts galactosylceramide transport, raft morphology, and lipid content.
Rusyn E; Mousallem T; Persaud-Sawin DA; Miller S; Boustany RM
Pediatr Res; 2008 Jun; 63(6):625-31. PubMed ID: 18317235
[TBL] [Abstract][Full Text] [Related]
29. Functional categorization of gene expression changes in the cerebellum of a Cln3-knockout mouse model for Batten disease.
Brooks AI; Chattopadhyay S; Mitchison HM; Nussbaum RL; Pearce DA
Mol Genet Metab; 2003 Jan; 78(1):17-30. PubMed ID: 12559844
[TBL] [Abstract][Full Text] [Related]
30. Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X).
Sarpong A; Schottmann G; Rüther K; Stoltenburg G; Kohlschütter A; Hübner C; Schuelke M
Clin Genet; 2009 Jul; 76(1):38-45. PubMed ID: 19489875
[TBL] [Abstract][Full Text] [Related]
31. CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease.
Luiro K; Kopra O; Lehtovirta M; Jalanko A
Hum Mol Genet; 2001 Sep; 10(19):2123-31. PubMed ID: 11590129
[TBL] [Abstract][Full Text] [Related]
32. Splicing variants in sheep CLN3, the gene underlying juvenile neuronal ceroid lipofuscinosis.
Oswald MJ; Palmer DN; Damak S
Mol Genet Metab; 1999 Jun; 67(2):169-75. PubMed ID: 10356317
[TBL] [Abstract][Full Text] [Related]
33. Neural and extraneural expression of the neuronal ceroid lipofuscinoses genes CLN1, CLN2, and CLN3: functional implications for CLN3.
Chattopadhyay S; Pearce DA
Mol Genet Metab; 2000; 71(1-2):207-11. PubMed ID: 11001812
[TBL] [Abstract][Full Text] [Related]
34. Cln3(Deltaex7/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth.
Cotman SL; Vrbanac V; Lebel LA; Lee RL; Johnson KA; Donahue LR; Teed AM; Antonellis K; Bronson RT; Lerner TJ; MacDonald ME
Hum Mol Genet; 2002 Oct; 11(22):2709-21. PubMed ID: 12374761
[TBL] [Abstract][Full Text] [Related]
35. Batten disease (JNCL) is linked to disturbances in mitochondrial, cytoskeletal, and synaptic compartments.
Luiro K; Kopra O; Blom T; Gentile M; Mitchison HM; Hovatta I; Törnquist K; Jalanko A
J Neurosci Res; 2006 Oct; 84(5):1124-38. PubMed ID: 16941499
[TBL] [Abstract][Full Text] [Related]
36. Neuronal vulnerability of CLN3 deletion to calcium-induced cytotoxicity is mediated by calsenilin.
Chang JW; Choi H; Kim HJ; Jo DG; Jeon YJ; Noh JY; Park WJ; Jung YK
Hum Mol Genet; 2007 Feb; 16(3):317-26. PubMed ID: 17189291
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3).
Aldrich A; Bosch ME; Fallet R; Odvody J; Burkovetskaya M; Rama Rao KV; Cooper JD; Drack AV; Kielian T
Ann Neurol; 2016 Dec; 80(6):909-923. PubMed ID: 27804148
[TBL] [Abstract][Full Text] [Related]
38. Intracellular trafficking of the JNCL protein CLN3.
Haskell RE; Derksen TA; Davidson BL
Mol Genet Metab; 1999 Apr; 66(4):253-60. PubMed ID: 10191111
[TBL] [Abstract][Full Text] [Related]
39. Gene symbol: CLN3. Disease: Juvenile neuronal ceroid lipofuscinosis (Batten disease).
Leman AR; Pearce DA; Rothberg PG
Hum Genet; 2005 May; 116(6):544. PubMed ID: 15991331
[No Abstract] [Full Text] [Related]
40. Gene symbol: CLN3. Disease: juvenile neuronal ceroid lipofuscinosis (Batten disease).
Leman AR; Pearce DA; Rothberg PG
Hum Genet; 2005 Feb; 116(3):236. PubMed ID: 15818814
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
